Literature DB >> 22371454

Biomarkers for EGFR-antagonist response: in the genes and on the genes!

Hariharan Easwaran1, Stephen B Baylin.   

Abstract

Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy. ©2012 AACR.

Entities:  

Mesh：

Year:  2012        PMID： 22371454      PMCID： PMC3586523          DOI： 10.1158/1078-0432.CCR-12-0157

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.

Authors:  Johannes R Kratz; Jianxing He; Stephen K Van Den Eeden; Zhi-Hua Zhu; Wen Gao; Patrick T Pham; Michael S Mulvihill; Fatemeh Ziaei; Huanrong Zhang; Bo Su; Xiuyi Zhi; Charles P Quesenberry; Laurel A Habel; Qiuhua Deng; Zongfei Wang; Jiangfen Zhou; Huiling Li; Mei-Chun Huang; Che-Chung Yeh; Mark R Segal; M Roshni Ray; Kirk D Jones; Dan J Raz; Zhidong Xu; Thierry M Jahan; David Berryman; Biao He; Michael J Mann; David M Jablons
Journal:  Lancet       Date:  2012-01-27       Impact factor: 79.321

2.  Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Authors:  Robert L Yauch; Thomas Januario; David A Eberhard; Guy Cavet; Wenjing Zhu; Ling Fu; Thinh Q Pham; Robert Soriano; Jeremy Stinson; Somasekar Seshagiri; Zora Modrusan; Chin-Yu Lin; Vincent O'Neill; Lukas C Amler
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

Review 3.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

4.  Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.

Authors:  Nancy Dumont; Matthew B Wilson; Yongping G Crawford; Paul A Reynolds; Mahvash Sigaroudinia; Thea D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

5.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

6.  Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

Authors:  Hidetaka Uramoto; Teruo Iwata; Takamitsu Onitsuka; Hidehiko Shimokawa; Takeshi Hanagiri; Tsunehiro Oyama
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

7.  Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

Authors:  Jenn-Yu Wu; Shang-Gin Wu; Chih-Hsin Yang; Yih-Leong Chang; Yeun-Chung Chang; Ya-Chieh Hsu; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Lung Cancer       Date:  2010-09-15       Impact factor: 5.705

Review 8.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

9.  Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Authors:  Chih-Hsin Yang; Chong-Jen Yu; Jin-Yuan Shih; Yeun-Chung Chang; Fu-Chang Hu; Meng-Chin Tsai; Kuan-Yu Chen; Zhong-Zhe Lin; Ching-Ju Huang; Chia-Tung Shun; Chin-Lun Huang; James Bean; Ann-Lii Cheng; William Pao; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

10.  Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Authors:  Barbara A Frederick; Barbara A Helfrich; Christopher D Coldren; Di Zheng; Dan Chan; Paul A Bunn; David Raben
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.